Products

SKOUT Software
Iterative Scopes
Gastroenterology AI
SKOUT Software by Iterative Scopes is an FDA-cleared AI-powered computer-aided detection (CADe) system that assists gastroenterologists in real-time polyp detection during colonoscopies, improving colorectal cancer screening and surveillance.

See all 1 product →

About Iterative Scopes

Iterative Scopes, now operating as Iterative Health, is an AI-driven healthcare technology company dedicated to transforming gastroenterology care. The company leverages advanced computer vision and machine learning algorithms to enhance diagnostic accuracy and streamline clinical workflows for physicians. Their core offerings include AI-powered endoscopic scoring systems designed to provide consistent, accurate, and individualized disease assessments.

For gastroenterologists, Iterative Scopes’ technology aims to improve the detection of abnormalities during procedures like endoscopies and colonoscopies, such as automated polyp detection for colorectal cancer screening. Additionally, their solutions standardize disease severity scoring for inflammatory bowel disease (IBD), which is crucial for optimizing patient management and accelerating clinical research. By integrating these AI tools, Iterative Scopes seeks to augment physician decision-making, reduce variability in interpretation, and ultimately improve patient outcomes by facilitating faster access to novel therapeutics through more efficient clinical trials.

Focus Areas

Gastroenterology Medical Imaging Diagnostics Clinical Trial Optimization Inflammatory Bowel Disease (IBD) Colorectal Cancer Screening Polyp Detection Endoscopic Scoring Systems Computer Vision Machine Learning

Business Intelligence

Key InvestorsInsight Partners, Clearlake Capital Group, Obvious Ventures, Johnson & Johnson Innovation – JJDC Inc., Eli Lilly and Co., Breyer Capital, 7wire Ventures, Addition, Bessemer Venture Partners, Curie.Bio, Lightbank, Operator Partners, Wavemaker Partners, Tau Ventures, p5hv, Frederic Kerrest, Seae Ventures, Micron Ventures, Time BioVentures, Valor Capital Group, Wavemaker 360, Nat Turner, Zach Weinberg
PartnershipsProvation, Eli Lilly and Company, Johnson & Johnson (Janssen Research & Development), One GI, GI Alliance, Gastro Health, US Heart & Vascular
AcquisitionsClinical Research Strategy Group, Precision Research
TechnologyAI-driven, computer vision, machine learning software, proprietary computational tools, AI-powered endoscopic scoring systems, cloud-native (implied)
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Gastroenterology Precision Medicine
Pioneers in applying AI-based precision medicine to gastroenterology, aiming to transform care, diagnosis, treatment, and research for various GI conditions.
Advanced Medical Imaging & Diagnostics
Utilizes powerful, proprietary AI and computer vision technologies to improve the accuracy and consistency of endoscopy readings. Their technology can identify over two dozen clinical features, including inflammation, ulcers, bleeding, and erosions.
Clinical Trial Optimization
Optimizes clinical trials for Inflammatory Bowel Disease (IBD) treatments by accelerating patient recruitment and standardizing disease severity characterization through AI-driven algorithms and computer vision.
Inflammatory Bowel Disease (IBD) Focus
Specializes in standardizing disease severity characterization for IBD, automating the scoring of metrics like the Mayo Endoscopic Score (MES) for clinical trial qualification, and working to establish more meaningful endpoints for GI diseases.
Colorectal Cancer Screening & Polyp Detection
Enhances colorectal cancer screenings through AI-assisted polyp detection. Their FDA-cleared SKOUTu2122 device uses advanced computer vision for real-time identification of suspicious tissue during colonoscopies, significantly improving adenoma detection rates.
Standardized Endoscopic Scoring Systems
Develops novel endoscopic scoring systems designed for greater consistency, accuracy, and individual reflection of GI diseases, improving upon traditional subjective methods for diagnosis and drug development.
Core AI, Computer Vision & Machine Learning
Their foundational technology stack leverages proprietary artificial intelligence, computer vision, and machine learning algorithms to analyze endoscopy images and videos, recognize suspicious tissue, automate scoring, and enhance diagnostic consistency.
Physician Tip

For physicians, Iterative Scopes (now Iterative Health) offers tools to significantly enhance diagnostic accuracy and consistency in gastroenterology. Leveraging their AI-assisted polyp detection device, SKOUTu2122, during colonoscopies can lead to improved adenoma detection rates and better patient outcomes in colorectal cancer screening, without increasing procedure time. Their standardized endoscopic scoring systems provide more objective and consistent assessments of GI diseases, particularly IBD, which can refine treatment decisions and patient management. For those involved in clinical research, their AI-driven recruitment services streamline patient identification and accelerate enrollment in IBD clinical trials, offering access to potentially life-changing new therapies. The technology acts as a powerful complement to physician expertise, enhancing pattern recognition and reducing variability in endoscopic interpretation.

Iterative Scopes actively collaborates with major pharmaceutical companies such as Pfizer, Janssen, and Eli Lilly to advance clinical trials and refine disease scoring algorithms. They maintain an exclusive partnership with Provation for the distribution of SKOUTu2122 and the integration of AI-based solutions into GI documentation software. Furthermore, strategic alliances with large gastroenterology management services organizations like One GIu00ae and Gastro Health aim to democratize access to their AI-based technology and standardize GI care across diverse clinical practices.

Products by Iterative Scopes

1 product in the directory

SKOUT Software
Iterative Scopes
Gastroenterology AI
SKOUT Software by Iterative Scopes is an FDA-cleared AI-powered computer-aided detection (CADe) system that assists gastroenterologists in real-time polyp detection during colonoscopies, improving colorectal cancer screening and surveillance.

What the Web Says

Iterative Scopes (also known as Iterative Health) is a company focused on transforming gastroenterology care and accelerating clinical research using AI. Their product, SKOUT, is an AI-assisted polyp detection device that has received FDA clearance and aims to improve the detection of pre-cancerous lesions during colonoscopies. The company is generally viewed as mission-driven with a focus on making a significant impact in healthcare. As an employer, it's described as a fast-growing startup with a dynamic environment.

Overall: Mixed

Strengths

  • Mission-driven work with a tangible impact on patient care.
  • Competitive compensation and benefits.
  • Opportunity to be part of building and making an impact in a growing company.
  • Team composed of dynamic and engaging colleagues.
  • Product (SKOUT) has shown to significantly improve adenoma detection during colonoscopies.
  • Focus on people-first workplace culture and strong teamwork.

Limitations

  • Fast-moving operating rhythms with shifting priorities can lead to change fatigue and being overwhelmed.
  • Heavy workloads and intensity are noted as recurring realities.
  • Some references to layoff anxiety and job insecurity as part of a growth company.
  • One review mentioned a toxic workplace created by amateurs in 2022.
  • A Reddit post raised concerns about a potential 'quid pro quo' offer to use the company's product, including legal fee reimbursement if caught, questioning its legality.
  • Limited reviews available on platforms like G2 and Capterra specifically for Iterative Scopes' products, making it difficult to gather widespread product-specific feedback.

Based on reviews from: Indeed.com, Forbes, G2.com, Fierce Biotech, Reddit, Built In

Last updated: 2026-07-18

Videos

News, demos, and interviews about Iterative Scopes.

Loading videos...

Videos load interactively. If none appear, search YouTube for Iterative Scopes →

View all on YouTube

Press & Coverage

Scope Forward
Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research
Iterative Health (formerly Iterative Scopes) secured $77 million in Series C funding to expand its AI-powered clinical research network beyond gastroenterology into areas like cardiology and obesity, aiming to improve clinical trial execution and patient enrollment.
2026-04
Iterative Health
Iterative Health and Gastroenterology Associates of New Jersey Partner to Expand Patient Access to Advanced GI Research
Iterative Health partnered with Gastroenterology Associates of New Jersey to broaden patient access to advanced GI research, leveraging AI to improve clinical trial recruitment.
2026-07
Business Wire
Iterative Scopes Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUTu2122
Iterative Scopes received 510(k) clearance from the FDA for its AI-assisted polyp detection device, SKOUTu2122, which uses computer vision to identify suspicious tissue during colonoscopies.
2022-09
Clearlake News
Iterative Scopes Announces $150 Million Series B to Advance AI-Driven Precision Medicine for Gastroenterology
Iterative Scopes raised $150 million in Series B financing, co-led by Insight Partners and Clearlake Capital, to accelerate the development of AI-driven precision medicine for gastroenterology, focusing on inflammatory bowel disease and colorectal cancer prevention.
2022-01
Iterative Health
Iterative Scopes Announces the Acquisition of Clinical Research Strategy Group and Precision Research
Iterative Scopes acquired Clinical Research Strategy Group and Precision Research, two companies specializing in optimizing clinical trials for inflammatory bowel disease (IBD), to strengthen its ties to the IBD research community and enhance its AI Recruitment service.
2022-04
PR Newswire
Iterative Scopes Announces Partnership with Eli Lilly and Company to Advance AI Applications for Inflammatory Bowel Disease (IBD) Clinical Trials
Iterative Scopes partnered with Eli Lilly and Company to advance AI applications for Inflammatory Bowel Disease (IBD) clinical trials, aiming to improve efficiency and reduce variability in endoscopic severity interpretation.
2021-02
Built In Boston
This Healthtech Startup Just Got $30M From Eli Lilly, Johnson & Johnson, Others
Iterative Scopes, an MIT spinout, secured $30 million in Series A funding from investors including Eli Lilly and Johnson & Johnson, to develop AI-enabled software for analyzing gastrointestinal images and videos to detect abnormalities.
2021-08
PR Newswire
Iterative Scopes Closes $5.2M Seed Fundraising Round
Iterative Scopes closed a $5.2 million seed funding round, led by Wavemaker Partners, to advance its proprietary computer vision technology for gastroenterology through clinical trials and commercialization.
2020-01

Frequently Asked Questions

Iterative Health (formerly Iterative Scopes) offers AI-powered solutions like SKOUTu2122, a real-time computer-aided polyp detection device that assists gastroenterologists during colonoscopies to improve the detection of potential colorectal polyps. They also provide AI Recruitment (AI-R) to optimize patient identification for Inflammatory Bowel Disease (IBD) clinical trials and are developing AI Documentation to streamline procedure reporting. These products leverage computer vision and machine learning to enhance the accuracy and consistency of endoscopy readings and diagnostic processes.
Iterative Health utilizes proprietary AI and computer vision technologies to standardize endoscopic scoring systems, such as the Mayo Endoscopic Score (MES), which are crucial for IBD clinical trial eligibility and endpoint measurement. Their AI Recruitment (AI-R) service accelerates patient identification and enrollment by analyzing colonoscopy imagery and videos to determine disease severity and match patients to appropriate trials more efficiently. This approach aims to reduce variability in interpretations and speed up the development of novel IBD therapeutics.
Iterative Health's flagship product for colorectal cancer screening is SKOUTu2122, an AI-driven medical device that uses advanced computer vision technology to detect potential colorectal polyps in real-time during colonoscopy examinations. SKOUT provides visual alerts to gastroenterologists, drawing attention to suspicious tissues and has demonstrated an increase in adenomas per colonoscopy compared to standard procedures. This technology aims to improve diagnostic accuracy and consistency in preventing colorectal cancer.
Iterative Health's SKOUT system has received FDA 510(k) clearance in the United States and a CE Mark in Europe, indicating compliance with medical device regulations. The company has also developed a comprehensive compliance program aligned with HHS OIG Compliance Program Guidance for Pharmaceutical Manufacturers and the PhRMA Code. While specific data security protocols are not publicly detailed, adherence to these regulatory frameworks implies robust measures for patient data protection and privacy.
Iterative Health offers professional services, including hands-on support for AI Recruitment implementation and assistance with clinical research workflows. They also provide 'Iterative U,' an on-demand training platform for clinical research teams, offering role-specific education and CE-eligible courses. The company actively partners with leading provider networks like One GI, GI Alliance, and US Heart & Vascular to expand access to clinical trials and integrate their AI tools into community-based practices.
Iterative Health has demonstrated strong financial stability, having raised a total of $185.2 million across three funding rounds, including a significant $150 million Series B in January 2022 from investors like Insight Partners, Clearlake Capital, Eli Lilly, and Johnson & Johnson. The company's long-term vision is to democratize access to high-quality GI care and accelerate the development of novel therapies by establishing more meaningful endpoints for GI diseases through AI-driven precision medicine. They aim to transform gastroenterology diagnosis, treatment, and research globally.

Investors

Who's funded Iterative Scopes.

Related Companies

Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]

Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]

Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]

Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]

Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]

SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.